Navigation Links
Vista Partners Updates Coverage; Maintains $3.20 Target Price
Date:10/13/2008

LOS ANGELES, Oct. 13 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationally continue to increase and sales from the Company's lab alliance, which give ABMC's products exposure in numerous testing centers, continue to increase as well. The Company recently received CLIA approval from the FDA. The CLIA approval will significantly broaden the Company's customer base and we believe ABMC's valuation will increase dramatically in the near future."

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About American Bio Medica Corporation:

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(R) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

Contact:

Vista Partners LLC

Jorden Lampos

(310) 744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics Posts Letter to Stockholders on Web Site
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
9. Vista Partners Updates Coverage; Maintains $3.20 Target Price
10. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
11. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse ... expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables ... is planned for further growth in 2017. Extractable & Leachable evaluations have become ...
(Date:1/18/2017)... Chicago, IL (PRWEB) , ... January 18, 2017 ... ... auction on January 24th, 2017, to sell research and genetic testing lab equipment ... of service in the Northwest and Northeast regions of the United States. This ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/6/2017)... 5, 2017  SomaLogic announced today that it ... established by iCarbonX, the China ... "Global Digital Health Ecosystem that can define each ... individual,s biological, behavioral and psychological data, the Internet ... companies, SomaLogic will provide proteomics data and applications ...
Breaking Biology News(10 mins):